異葒草素作用機(jī)制 - Medchemexpress - MCE中國(guó)_第1頁(yè)
異葒草素作用機(jī)制 - Medchemexpress - MCE中國(guó)_第2頁(yè)
異葒草素作用機(jī)制 - Medchemexpress - MCE中國(guó)_第3頁(yè)
全文預(yù)覽已結(jié)束

異葒草素作用機(jī)制 - Medchemexpress - MCE中國(guó).docx 免費(fèi)下載

版權(quán)說(shuō)明:本文檔由用戶(hù)提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請(qǐng)進(jìn)行舉報(bào)或認(rèn)領(lǐng)

文檔簡(jiǎn)介

1、Product Data SheetIsoorientinCat. No.: HY-N0767CAS No.: 4261-42-1分式: CHO分量: 448.38作靶點(diǎn): COX作通路: Immunology/Inflammation儲(chǔ)存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實(shí)驗(yàn) DMSO : 100 mg/mL (223.03 mM)* means soluble, but saturation unknown.SolventMass1 mg 5 mg 10 mgConcentr

2、ation制備儲(chǔ)備液1 mM 2.2303 mL 11.1513 mL 22.3025 mL5 mM 0.4461 mL 2.2303 mL 4.4605 mL10 mM 0.2230 mL 1.1151 mL 2.2303 mL請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液;旦配成溶液,請(qǐng)分裝保存,避免反復(fù)凍融造成的產(chǎn)品失效。儲(chǔ)備液的保存式和期限:-80C, 6 months; -20C, 1 month。-80C 儲(chǔ)存時(shí),請(qǐng)?jiān)?6 個(gè)內(nèi)使,-20C 儲(chǔ)存時(shí),請(qǐng)?jiān)?1 個(gè)內(nèi)使。體內(nèi)實(shí)驗(yàn)請(qǐng)根據(jù)您的實(shí)驗(yàn)動(dòng)物和給藥式選擇適當(dāng)?shù)娜芙獍?。以下溶解案都?qǐng)先按照 In Vitro 式配制澄清的儲(chǔ)備

3、液,再依次添加助溶劑:為保證實(shí)驗(yàn)結(jié)果的可靠性,澄 的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件,適當(dāng)保存;體內(nèi)實(shí)驗(yàn)的作液,建議您現(xiàn)現(xiàn)配,當(dāng)天使; 以下溶劑前顯的百分 指該溶劑在您配制終溶液中的體積占;如在配制過(guò)程中出現(xiàn)沉淀、析出現(xiàn)象,可以通過(guò)加熱和/或超聲的式助溶1. 請(qǐng)依序添加每種溶劑: 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 2.5 mg/mL (5.58 mM); Clear solution此案可獲得 2.5 mg/mL (5.58 mM,飽和度未知) 的澄清溶液。以 1 mL 作液為例,取 100 L 25.0 mg/mL 的澄 DMS

4、O 儲(chǔ)備液加到 400 L PEG300 中,混合均勻;向上述體系中加50 L Tween-80,混合均勻;然后繼續(xù)加 450 L 理鹽定容 1 mL。2. 請(qǐng)依序添加每種溶劑: 10% DMSO 90% (20% SBE-CD in saline)Solubility: 2.5 mg/mL (5.58 mM); Clear solutionPage 1 of 2 www.MedChemE此案可獲得 2.5 mg/mL (5.58 mM,飽和度未知) 的澄清溶液。以 1 mL 作液為例,取 100 L 25.0 mg/mL 的澄 DMSO 儲(chǔ)備液加到 900 L 20% 的 SBE-CD 理鹽

5、溶液中,混合均勻。BIOLOGICAL ACTIVITY物活性 Isoorientin種有效的 COX-2 抑制劑,IC50 值為 39 M。IC & Target COX-239 M (IC50)體外研究 Isoorientin is a Selective Inhibitor of Cyclooxygenase-2 (COX-2) from the Tubers of Pueraria tuberosa1. PANC-1 andPATU-8988 cells are grown for 24 hours in the presence of Isoorientin (0, 20, 40,

6、80, and 160 M), and a CCK8solution is added. The cell viability decreases significantly at the concentrations of 20, 40, 80, and 160 M. After thecells are cultured with Isoorientin (0, 20, 40, 80, and 160 M for PANC-1; 0, 20, 40, 80, 160, and 320 M for PATU-8988) for 24 hours, the expression of p-AM

7、PK and AMPK is assessed by Western blotting. After the Isoorientintreatment, the p-AMPK expression is increased. Then, in the shRNA group, the concentration of 80 M is used todetect the effects of Isoorientin. The expression levels of AMPK and p-AMPK are much lower in the shRNA group thanin the wild

8、-type PC cells (WT) and the group that is transfected with a negative control lentivirus (NC)2.體內(nèi)研究 Animals treated with Isoorientin at 10 mg/kg and 20 mg/kg body weight have a statistically significant reduction inpaw edema, with a mean peak thickness of 1.190.05 mm and 1.080.04 mm, respectively. T

9、his indicated thatIsoorientin significantly attenuates paw edema compared with the control group3.PROTOCOLCell Assay 2 PANC-1 and PATU-8988 cells are plated onto 96-well plates. Each well contain 5,000 cells and 200 L of themedium with 10% FBS. When the cells of each well reach 70% confluency, the m

10、edium is changed, and FBS-freemedium with different concentrations of Isoorientin is added. After 24 hours, the cells are washed with PBS once, themedium containing Isoorientin is discarded, and 100 L of FBS-free medium with 10 L of the Cell Counting Kit 8(CCK8) reagent are added. The cells are incu

11、bated for another 1-2 hours at 37C, and the absorbance of each well isdetected using an ELISA reader at 490 nm. Cell viability is expressed as the fold change of absorbance2.MCE has not independently confirmed the accuracy of these methods. They are for reference only.Animal Mice3Administration 3 In

12、 the case of paw edema model the Isoorientin or Celecoxib is given intraperitoneally and Carrageenan is injectedinto the paw directly one hour later. In air pouch model all the treatments are given along with Carrageenan directlyinto the pouch cavity. Isoorientin is injected three hours earlier than

13、 injection of Carrageenan into the pouch cavity.Isoorientin and Celecoxib are administered into the mice air pouch. The stock solutions of Isoorientin (100 mg/mL)and Celecoxib (100 mg/mL) are prepared in DMSO and further dilutions are made at the time of treatments. Animalsare divided, into 5 differ

14、ent groups as follows: control (DMSO treated); Carrageenan (0.5 mL of 1.5% (w/v)Carrageenan in saline) treated; Carrageenan+Celecoxib (20 mg/kg body weight) treated; Carrageenan+Isoorientin (10mg/Kg body weight) treated; Carrageenan+Isoorientin (20 mg/Kg body weight) treated.MCE has not independentl

15、y confirmed the accuracy of these methods. They are for reference only.REFERENCESPage 2 of 3 www.MedChemE1. Sumalatha M, et al. Isoorientin, a Selective Inhibitor of Cyclooxygenase-2 (COX-2) from the Tubers of Pueraria tuberosa. Nat Prod Commun. 2015Oct;10(10):1703-4.2. Ye T, et al. Isoorientin indu

16、ces apoptosis, decreases invasiveness, and downregulates VEGF secretion by activating AMPK signaling in pancreatic cancercells. Onco Targets Ther. 2016 Dec 12;9:7481-7492.3. Anilkumar K, et al. Evaluation of Anti-Inflammatory Properties of Isoorientin Isolated from Tubers of Pueraria tuberosa. Oxid Med Cell Longe

溫馨提示

  • 1. 本站所有資源如無(wú)特殊說(shuō)明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請(qǐng)下載最新的WinRAR軟件解壓。
  • 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請(qǐng)聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶(hù)所有。
  • 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁(yè)內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒(méi)有圖紙預(yù)覽就沒(méi)有圖紙。
  • 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
  • 5. 人人文庫(kù)網(wǎng)僅提供信息存儲(chǔ)空間,僅對(duì)用戶(hù)上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對(duì)用戶(hù)上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
  • 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請(qǐng)與我們聯(lián)系,我們立即糾正。
  • 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶(hù)因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。

最新文檔

評(píng)論

0/150

提交評(píng)論